James Orsborne
Stock Analyst at Stifel Nicolaus
(0.21)
# 4,170
Out of 4,334 analysts
54
Total ratings
37.5%
Success rate
-16.2%
Average return
Main Sectors:
Stocks Rated by James Orsborne
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: OXB Oxford Biomedica plc | Reiterated: Buy | $725 → $950 | $618.00 | +53.72% | 10 | Mar 11, 2026 | |
| LON: ONT Oxford Nanopore Technologies plc | Upgraded: Hold | $100 → $140 | $129.40 | +8.19% | 9 | Jan 8, 2026 | |
| AIM: STX Shield Therapeutics plc | Upgraded: Buy | $3.8 → $0.1 | $6.35 | -98.43% | 4 | Oct 6, 2025 | |
| AIM: FUM Futura Medical plc | Reiterated: Buy | $140 | $0.67 | n/a | 7 | Apr 15, 2025 | |
| AIM: NIOX NIOX Group Plc | Maintained: Buy | $77 | $59.20 | n/a | 6 | Apr 11, 2025 | |
| AIM: HVO hVIVO plc | Reiterated: Buy | $30 | $8.10 | n/a | 11 | Apr 10, 2025 | |
| LON: HLN Haleon plc | Maintained: Hold | $340 → $370 | $343.80 | n/a | 4 | Feb 25, 2025 | |
| EPA: VLA Valneva SE | Reiterated: Buy | $6.5 | $2.61 | n/a | 1 | Sep 25, 2024 | |
| AIM: SCLP Scancell Holdings plc | Rated: Buy | $30 | $22.00 | n/a | 2 | Sep 19, 2023 |
Oxford Biomedica plc
Mar 11, 2026
Reiterated: Buy
Price Target: $725 → $950
Current: $618.00
Upside: +53.72%
Oxford Nanopore Technologies plc
Jan 8, 2026
Upgraded: Hold
Price Target: $100 → $140
Current: $129.40
Upside: +8.19%
Shield Therapeutics plc
Oct 6, 2025
Upgraded: Buy
Price Target: $3.8 → $0.1
Current: $6.35
Upside: -98.43%
Futura Medical plc
Apr 15, 2025
Reiterated: Buy
Price Target: $140
Current: $0.67
Upside: n/a
NIOX Group Plc
Apr 11, 2025
Maintained: Buy
Price Target: $77
Current: $59.20
Upside: n/a
hVIVO plc
Apr 10, 2025
Reiterated: Buy
Price Target: $30
Current: $8.10
Upside: n/a
Haleon plc
Feb 25, 2025
Maintained: Hold
Price Target: $340 → $370
Current: $343.80
Upside: n/a
Valneva SE
Sep 25, 2024
Reiterated: Buy
Price Target: $6.5
Current: $2.61
Upside: n/a
Scancell Holdings plc
Sep 19, 2023
Rated: Buy
Price Target: $30
Current: $22.00
Upside: n/a